Chronic Hepatitis B Market
Feb 13, 2024
GSK Receives FDA Fast Track Designation for Bepirovirsen; Gilead to Acquire CymaBay Therapeutics; CSL Announces Top-line Results from the Phase III AEGIS-II Trial; Ruxoprubart Scores FDA Orphan Drug Designation for PNH Treatment; CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar; Biogen Received European Commission Approval for SKYCLARYS
GSK Receives FDA Fast Track Designation for Bepirovirsen in Chronic Hepatitis B GSK plc has revealed that the US Food and Drug Administration (FDA) has awarded Fast Track status to bepirovirsen, an experimental antisense oligonucleotide (ASO) designed to treat chronic hepatitis B (CHB). Fast Track designation ai...
Read More...
Jan 04, 2021
Search for the Cure Continues in the Chronic Hepatitis B Treatment Market
Hepatitis B virus (HBV) infection is the 10th leading cause of death worldwide. With 2 billion people infected all over, HBV infection is a reason behind 500 000 to 1.2 million deaths per year. Hepatitis B is a lethal infection and has been a major global problem for years. If it lasts for over 6 months, it is term...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
